According to Intra-Cellular Therapies's latest financial reports the company's current earnings (TTM) are -$0.14 B. In 2022 the company made an earning of -$0.26 B an increase over its 2021 earnings that were of -$0.29 B.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$0.14 B | -45.74% |
2022 | -$0.26 B | -9.81% |
2021 | -$0.29 B | 25.17% |
2020 | -$0.23 B | 53.66% |
2019 | -$0.15 B | -4.77% |
2018 | -$0.16 B | 56.96% |
2017 | -$98.84 M | -14.33% |
2016 | -$0.12 B | 10.09% |
2015 | -$0.11 B | 241.45% |
2014 | -$30.69 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Xencor XNCR | -$0.13 B | -13.38% | ๐บ๐ธ USA |
MediciNova MNOV | -$8.57 M | -93.84% | ๐บ๐ธ USA |
Curis CRIS | -$43.93 M | -68.41% | ๐บ๐ธ USA |